Tango Therapeutics Inc (TNGX)vsVertex Pharmaceuticals Inc (VRTX)
TNGX
Tango Therapeutics Inc
$20.88
+7.19%
HEALTHCARE · Cap: $2.98B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 19138% more annual revenue ($12.00B vs $62.38M). VRTX leads profitability with a 32.9% profit margin vs -162.9%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
TNGX
Avoid20
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for TNGX.
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.2x book value
0.0% earnings growth
ROE of -37.2% — below average capital efficiency
Revenue declined 100.0%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : TNGX
TNGX has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : TNGX
The primary concerns for TNGX are Price/Book, EPS Growth, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
TNGX profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
TNGX carries more volatility with a beta of 1.81 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 20/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Tango Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tango Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of targeted therapies aimed at addressing significant unmet needs in cancer treatment, particularly through the innovative concept of synthetic lethality. With a diverse pipeline of promising drug candidates, Tango is well-positioned to lead advancements in precision oncology, focusing on collaborative partnerships with leading research institutions to enhance its scientific capabilities. The company's strategic vision is to transform cancer care and improve patient outcomes, positioning it as a key player in the evolution of treatment paradigms in oncology.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?